Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.

Journal of clinical pharmacy and therapeutics - 1 Oct 2020

Yau Wing Hing, Ameratunga Malaka

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: Post-surgical management of low grade gangliogliomas is controversial with paucity of data for the use of chemotherapy. BRAF mutations are present in a number of glioma subtypes and offer an opportunity for treatment with targeted therapy. CASE SUMMARY: A 32-year-old man with an unresectable, BRAF V600E mutant, WHO grade 1 ganglioglioma is commenced on combination BRAF and MEK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Ganglioglioma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Piperidines

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Identifiers

PMID: 31985841
DOI: 10.1111/jcpt.13112

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.PMID 31985841Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.Semantic proximity Read ↗

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.Semantic proximity Read ↗

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain TumorsSemantic proximity Read ↗

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationSemantic proximity Read ↗

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal TumorsSemantic proximity Read ↗

Ganglioglioma with MAP2K1 Mutation and CDKN2A/B Homozygous Deletion: A Case Report.Semantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.Semantic proximity Read ↗

Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.Semantic proximity Read ↗

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.Semantic proximity Read ↗

BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.